Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy

Glioblastoma (GBM), the most aggressive primary brain tumor, remains a formidable therapeutic challenge, with a median survival under 15 months. Despite the current standard of care-comprising maximal safe surgical resection, radiotherapy, and temozolomide chemotherapy-patient outcomes have seen min...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Songlei Zhou, Xiaokun Zhang, Jiayi Lin, Fenfen Ma, Hongzhuan Chen, Jun Chen, Xin Luan
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2026-03-01
Rangatū:	Acta Pharmaceutica Sinica B
Ngā marau:	Glioblastoma Systemic immunosuppression Local immunosuppression Tumor microenvironment Immunotherapy Lymphopenia
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2211383526000389
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!